Cephalosporins changing resistance patterns clsi guidelines 2010
Download
1 / 46

Cephalosporins and Antibiotic Resistance - PowerPoint PPT Presentation


  • 960 Views
  • Uploaded on

Cephalosporins and Antibiotic Resistance

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Cephalosporins and Antibiotic Resistance' - doctorrao


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Cephalosporins changing resistance patterns clsi guidelines 2010 l.jpg

CEPHALOSPORINSchanging resistance patterns CLSI Guidelines 2010

Dr.T.V.Rao MD

Dr.T.V.Rao MD


Introduction to cephalosporins l.jpg
Introduction to Cephalosporins..

Cephalosporins were first isolated from cultures of Cephalosporium acremonium from a sewer in 1948 by Italian scientist, Giuseppe Brotzu

The first agent cephalothin (cefalotin) was launched by Eli Lilly in 1964

Dr.T.V.Rao MD


Cephalosporins l.jpg
Cephalosporins ….

  • B-Lactam antibiotics ( similar to penicillin's)

  • Broad spectrum in action.

  • Act by inhibition of cell wall synthesis

  • Bactericidal

  • Inactive against : enterococci, MRSA, legionella , mycoplasma, chlamydia spp.

  • Widely used in surgical procedures to reduce the risk of post operative infections

Dr.T.V.Rao MD


Antimicrobial activity of cephalosporins l.jpg
Antimicrobial activity of Cephalosporins

  • The site of action of beta-lactam antibiotics is the penicillin binding proteins (PBPs) on the inner surface of the bacterial cell membrane that are involved in the synthesis of the cell wall

    Cephalosporins are bactericidal agents

    All bacterial cells have a cell wall that protects them. Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls, which causes the walls to break down and eventually the bacteria die.

Dr.T.V.Rao MD


Classification is based on spectrum of activity l.jpg
Classification is based on spectrum of activity

Cephalosporins are grouped into "generations" based on their spectrum of antimicrobial activity.

The first cephalosporins were designated first generation while later, more extended spectrum cephalosporins were classified as second generation cephalosporins.

So continued Generations

Dr.T.V.Rao MD


Basis of classification l.jpg
Basis of Classification

Each newer generation of cephalosporins has significantly greater gram-negative antimicrobial properties than the preceding generation

Fourth generation cephalosporins, however, have true broad spectrum activity

Dr.T.V.Rao MD


1 st generation c ephalosporins l.jpg
1st generation Cephalosporins

First generation cephalosporins are moderate spectrum agents

Effective against gram +ve aerobes

They are effective for treating staphylococcal and streptococcal infections and therefore are alternatives for skin and soft-tissue infections, as well as for streptococcal pharyngitis.

Dr.T.V.Rao MD


The 1 st generation cephalosporins are l.jpg
The 1st generation cephalosporins are:

  • Cefadroxil

  • Cephalexin

  • Cephaloridine

  • Cephalothin

  • Cephapirin

  • Cefazolin

  • Cephradine

Dr.T.V.Rao MD


1 st generation l.jpg
1st Generation

Active against G+ cocci ( except. Enterococci & MRSA ):

s.pneumoniae, s.pyogenes,s. aureus, S. epidermidis

Indicated for streptococcal pharyngitis ( e.g. cephalexin)

Commonly used ( eg. Cefazolin) as prophylactic for surgical procedures.

Modest activity against G- bacteria

Dr.T.V.Rao MD


2 nd generation cephalosporins l.jpg
2nd generation Cephalosporins

  • Their antibacterial spectrum is broader than that of 1st generation cephalosporins and includes some gram -ve pathogens

  • They are also more resistant to beta-lactamase

  • They are useful agents for treating upper and lower respiratory tract infections and sinusitis

Dr.T.V.Rao MD


2 nd generation cont l.jpg
2nd generation cont...

These agents are also active against E. coli, Klebsiella and Proteus, which makes them potential alternatives for treating urinary tract infections caused by these organisms

Dr.T.V.Rao MD


2 nd generation cephalosporins12 l.jpg
2nd Generation Cephalosporins ..

Cefoxitin

Cefuroxime Cefuroxime axetil

Cefaclor Cefprozil

Dr.T.V.Rao MD


3 rd generation cephalosporins l.jpg
3rd generation Cephalosporins

  • They have an extended spectrum of action against gram -ve organisms

  • Resistant to beta-lactamases

Dr.T.V.Rao MD


3 rd generation cont l.jpg
3rd generation cont...

  • The parenteral third generation cephalosporins (ceftriaxone and cefotaxime) have excellent activity against most strains of Streptococcus pneumoniae, including the vast majority of those with intermediate and high level resistance to penicillin

Dr.T.V.Rao MD


Third generation cephalosporins l.jpg
Third Generation Cephalosporins

Ceftriaxone

Cefotaxime

Ceftazidime

Cefoperazone

Cefixime

Dr.T.V.Rao MD


Third generation l.jpg
THIRD GENERATION

They have enhanced G- activity, H. influenza, N. meningitidis, N.gonorrhea, P. aeruginosae, M. catarrhalis, E.coli, most Klebsiella

Ceftriaxone has long half-life . Not advised in neonates (interferes with bilirubin metabolism )

Cefotaximepreferred in neonate ( does not interfere with bilirubin metabolism ), as may ceftriaxone.

Ceftazidime& cefoperazone have excellent activity against P.aeruginosa.

Cefixime has similar activity to amoxicillin & Cefaclor for actute otitis media

Dr.T.V.Rao MD


4 th generation cephalosporins l.jpg
4th generation cephalosporins

  • 4th generation cephalosporins are extended spectrum agents with similar activity against gram-positive organisms as first generation cephalosporins.

  • They also have a greater resistance to beta-lactamases than the third generation cephalosporins.

  • Many can cross blood brain barrier and are effective in meningitis.

Dr.T.V.Rao MD


4 th generation cephalosporins18 l.jpg
4th Generation Cephalosporins...

  • Cefepime

  • Cefluprenam

  • Cefozopran

  • Cefpirome

  • Cefquinome

Dr.T.V.Rao MD


Fourth gener ation cefipime l.jpg
Fourth GenerationCefipime

Active against G+ bacteria > than Cefazolin against s. pyogenes, S.pneumoniae but lower against s. aureus. Similar to cefotaxime against E.coli & K. pneumoniae but < for p. aeruginosa.

Dr.T.V.Rao MD


Pharmacokinetic consideration l.jpg
Pharmacokinetic consideration

  • They are organic acids and are hydrophilic

  • They generally have poor oral bioavailability as they unstable in acid environments

  • They are readily excreted by the kidneys, via tubular secretion in the proximal convoluted tubule. This results in high concentrations of the drug in urine.

  • Exceptions are:

  • Cephalexin which is stable in acid and so suitable for oral dosing.

  • Cefoperazone is excreted in bile rather than in urine.

Dr.T.V.Rao MD


Why cephalosporins are widely p rescribed a ntibiotics l.jpg
Why Cephalosporins are Widely Prescribed Antibiotics

  • Broad spectrum of activity

  • Stability to -lactamase

  • Oral and parenteral preparations

  • Widely accepted

  • Treats ‘day to day’ as well as‘serious infections’

  • High safety profile

Dr.T.V.Rao MD


Cephalosporins limitations l.jpg
Cephalosporins-Limitations

  • Emerging resistance patterns

  • III & IV generation cephalosporins were available only as parenteral formulations

  • Pharmacoeconomics

Dr.T.V.Rao MD


Why detect esbl producers l.jpg
Why detect ESBL producers?

  • ESBL producers may:

  • Appear Sensitive to some cephalosporins in vitro

  • Show major inoculum effects

  • Fail in therapy, despite appearing susceptible

Dr.T.V.Rao MD


Detection strategy step 1 l.jpg
Detection Strategy: step 1

  • Screen Enterobacteriaceae with :

  • Cefpodoxime- best general ESBL substrate

  • Cefotaxime & ceftazidime- good substrates for CTX-M & TEM/SHV, respectively

Spread of CTX-M into community means screening must be wider than before

Ref http://www.hpa.org.uk

Dr.T.V.Rao MD


Detection of esbls step 2 l.jpg
Detection of ESBLs: step 2

  • Seek ceph/clav synergy in ceph R isolates

    • Double disc

    • Combination disc

    • Etest

Ref http://www.hpa.org.uk

Dr.T.V.Rao MD


Double disk method l.jpg
Double Disk Method

Dr.T.V.Rao MD


Slide27 l.jpg

Etest for ESBLs

Cefotaxime

Cefotaxime

+

Clavulanate

Dr.T.V.Rao MD


Pitfalls in esbl detection l.jpg
Pitfalls in ESBL detection

  • Methods optimised for E. coli & Klebsiella

  • More difficult with Enterobacter

    • clavulanate induces AmpC; hides ESBL

  • Best advice is to do synergy test (NOT SCREEN) with 4th gen cephalosporins

Dr.T.V.Rao MD


Synergy tests with 4 gen cephalosporins l.jpg
Synergy tests with 4-gen cephalosporins

  • Cefepime/clav (Mast & AB Biodisk)

  • Cefpirome clav (Oxoid)

    • Devt. driven by spread of clonal E. aerogenes with TEM-24 in Belgium & France

    • Sensitivity for weak ESBLs remains to be proven

    • Cefpirome & cefepime products need comparison

Dr.T.V.Rao MD


Bacteria not to test for esbls l.jpg
Bacteria not to test for ESBLs

  • Acinetobacter

    • Often S to clavulanate alone

  • S. maltophilia

    • +ve result by inhibition of L-2 chromosomal b-lactamase, ubiquitous in the species

Dr.T.V.Rao MD


Role of clsi in revising breakpoints in antibiotic resistance l.jpg
Role of CLSI in Revising Breakpoints in Antibiotic Resistance

  • Briefly, revising breakpoints involves systematic review of microbiological, pharmacologic, and clinical data. Recognized experts, sponsors (pharmaceutical industry), and regulators participate in the process which includes discussions at public meetings of the CLSI Subcommittee on Antimicrobial Susceptibility Testing that take place twice a year. When establishing original breakpoints for new agents, controlled clinical trial data are required

Dr.T.V.Rao MD


Follow the new guidelines clsi 2010 l.jpg
Follow the New Guidelines CLSI 2010 Resistance

  • Guidelines for cephalospins for Enterobacteriaceae in accordance with the 2010 Clinical Laboratory Standards Institute (CLSI) recommendations. The following changes will be made to comply with the CLSI.

Dr.T.V.Rao MD


Why do breakpoints sometimes need to be revised l.jpg
Why do breakpoints sometimes need to be revised? Resistance

  • Breakpoints need to be revised due to changing resistance mechanisms and bacterial population distributions, changing science leading to a better understanding of the pharmacologic determinants of clinical response, and adoption of “best practices” by clinicians.

Dr.T.V.Rao MD


Enterobacteriaceae r apid s pread of resistance l.jpg
Enterobacteriaceae Resistance- Rapid Spread of resistance

  • The rapid and disturbing spread of:

    • extended-spectrum ß-lactamases

    • AmpC enzymes

    • carbapenem resistance

      • metallo-β-lactamases

      • KPC and OXA-48 β-lactamases

    • quinolone resistance

Dr.T.V.Rao MD


What breakpoints were revised in 2010 l.jpg
What breakpoints were revised in 2010? Resistance

  • Select cephalosporin and aztreonam breakpoints for Enterobacteriaceae were revised as noted below (for comparison, the old breakpoints are included):

Dr.T.V.Rao MD


Extended spectrum lactamases l.jpg
Extended-Spectrum Resistanceβ-Lactamases

  • β-lactamases capable of conferring bacterial resistance to

    • the penicillin's

    • first-, second-, and third-generation cephalosporins

    • aztreonam

    • (but not the cephamycins or carbapenems)

  • These enzymes are derived from group 2b β-lactamases (TEM-1, TEM-2, and SHV-1)

    • differ from their progenitors by as few as one AA

Dr.T.V.Rao MD


Ct ctx m type esbls x m type esbls l.jpg
CT ResistanceCTX-M-type ESBLs X-M-type ESBLs

  • Until 2000, most ESBL producers were hospital Klebsiella spp. with TEM and SHV mutant β-lactamases

  • Now, the dominant ESBLs across most of Europe and Asia are CTX-M enzymes, which originated as genetic escapes from Kluyvera spp

  • Currently recognized as the most widespread and threatening mechanism of antibiotic resistance, both in clinical and community settings

    • 80% of ESBL-positive E. coli from bacteraemias in the UK and Ireland are resistant to fluoroquinolones

    • 40% are resistant to gentamicin

Dr.T.V.Rao MD

Livermore, DM J. Antimicrob. Chemother 2009


Enterobacteriaceae revised breakpoints for cephalosporins l.jpg
Enterobacteriaceae Resistance: Revised Breakpoints for Cephalosporins

Dr.T.V.Rao MD


Disk diffusion breakpoints mm l.jpg
Disk diffusion breakpoints (mm): Resistance

  • Agent Old (M100-S19) Revised (M100-S20)

    S I R S I R

  • Cefazolin ≥18 15-17 ≤14 NA NA NA

  • Cefotaxime ≥23 15-22 ≤14 ≥26 23-25 ≤22

  • Ceftizoxime ≥20 15-19 ≤14 ≥25 22-24 ≤21

  • Ceftriaxone ≥21 14-20 ≤13 ≥23 20-22 ≤19

  • Ceftazidime ≥18 15-17 ≤14 ≥21 18-20 ≤17

  • Aztreonam ≥22 16-21 ≤15 ≥21 18-20 ≤17

  • S – susceptible

  • I – Intermediate

  • R – Resistant.

Dr.T.V.Rao MD


F ollowing mic breakpoints were reevaluated for enterobacteriaceae but were not revised l.jpg
F Resistanceollowing MIC breakpoints were reevaluated for Enterobacteriaceae but were not revised

  • Agent M100-S19 M100-S20

    S I R S I R

  • Cefuroxime ≤8 16 ≥32 ≤8 16 ≥32

  • Cefepime ≤8 16 ≥32 ≤8 16 ≥32

  • Cefotetan ≤16 32 ≥64 ≤16 32 ≥64

  • Cefoxitin ≤8 16 ≥32 ≤8 16 ≥32

  • S – susceptible

  • I – Intermediate

  • R – Resistant

Dr.T.V.Rao MD


Why were the breakpoints for cefepime and cefuroxime parenteral not revised l.jpg
Why were the breakpoints for cefepime and cefuroxime (parenteral) not revised?

  • The cefepime breakpoints were not revised based upon clinical trial data and PK-PD evaluations. The clinical trial data showed cefepime efficacy for patients infected with isolates that tested cefepime susceptible (MIC ≤8 μg/ml), but produced an ESBL

Dr.T.V.Rao MD


Why are there no disk diffusion breakpoints for cefazolin l.jpg
Why are there no disk diffusion breakpoints for (parenteral) not revisedCefazolin?

  • Studies have not yet been completed to identify the zone diameter breakpoints that correlate with the revised MIC breakpoints for Cefazolin. Initial studies did not reveal clear zone diameter breakpoints and disk diffusion testing of Cefazolin may require a new disk with alternate disk content.

Dr.T.V.Rao MD


Cephalothin group l.jpg
Cephalothin group (parenteral) not revised

  • Cephalothin is now classified under Test/Report Group U for Enterobacteriaceae. Results for cephalothin can be used to represent activities of several other oral FDA-approved agents for treatment of urinary tract infections which include cefadroxil, cefpodoxime, cephalexin, and loracarbef.

Dr.T.V.Rao MD


Need for changing recommendations l.jpg
Need for Changing (parenteral) not revisedRecommendations

  • The ESBL testing recommendations were to be a short term solution to address a new mechanism of resistance. Subsequently, additional mechanisms of resistance have been identified (e.g., new types of ESBLs and AmpC-like enzymes) and with increased frequency multiple enzymes are identified in a single isolate which can complicate ESBL testing (1). These issues coupled with improved understanding of the PK-PD determinants of efficacy with cephalosporins and monobactams resulted in the decision to revise the breakpoints.

Dr.T.V.Rao MD


Measuring the revised zones is advantageous l.jpg
Measuring the Revised Zones is Advantageous (parenteral) not revised

  • The revised breakpoints eliminate the need to perform ESBL screen and confirmatory tests for making treatment decisions. Phenotypic tests for ESBL detection and confirmation are less accurate when multiple enzymes are present (e.g., false-negative results occur when isolates express both ESBLs and AmpC-type enzymes) (13) and the presence of multiple enzymes are more common in contemporary isolates (4, 8). The MIC of an isolate correlates better with clinical outcome than knowledge of resistance mechanisms (e.g., ESBLs)

Dr.T.V.Rao MD


Slide46 l.jpg

  • Programme Created by Dr.T.V.Rao MD for ‘e’ learning resources for Medical and Paramedical Students in Developing world

  • Email

  • [email protected]

Dr.T.V.Rao MD


ad